Hydronidone for long-term treatment of hepatitis B scarring
Treatments studied
Part of Digestive system clinical trials.
This Phase 3 study tests whether hydronidone capsules can help people with long-term hepatitis B–related liver scarring (fibrosis). It aims to track whether treatment reduces or delays serious liver complications over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have hepatitis B with liver scarring (fibrosis) and be able to join this Phase 3 study protocol
- Be willing to complete the main treatment course and attend the final study visit
- Understand the study and sign consent, with good ability to communicate and follow study visits and rules
- Must not have a major liver “endpoint” event happen during the Phase 3 trial period (serious progression or complications)
- Not have other cancers (except liver cancer) with an expected survival under 1 year
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a long-term treatment called hydronidone for liver scarring (fibrosis) caused by chronic hepatitis B. It aims to see if the treatment can help slow or reverse liver damage in people who are already on antiviral therapy or starting treatment for the first time.
This trial tests a new medicine called Hydronidone Capsule in healthy people to see how the body processes it and whether it is safe. If you are in good health, you may be able to join this first-in-human study.
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
This study looks at better ways to predict significant liver fibrosis (scarring) in people with chronic hepatitis B or non-alcoholic fatty liver disease. It aims to help avoid invasive tests like liver biopsy.
This study tests how a drug called hydronidone is processed and removed from the body using a very small amount of radioactive labeling. It helps researchers understand how the drug works, so it may lead to better treatments for conditions like liver fibrosis.
This Phase 2 trial tests an injection medicine (F573) to see if it can improve people with liver injury, drug-related liver damage, or liver failure. You may be screened with blood tests, liver stiffness measurements, and possibly symptom checks.
Hear when a new Liver Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.